| Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required. | |
| | |
MedLine Citation:
|
PMID: 11067719 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
(1) Interferon beta-1b is now licensed to treat patients with secondary progressive multiple sclerosis. (2) The clinical file that we compiled on this indication, includes a double-blind placebo-controlled trial in which 718 patients were treated for 2-3 years. The trial is methodologically sound. (3) In this trial, interferon beta-1b, at the only dose tested (8 MIU every two days by the subcutaneous route), significantly reduced the progression of the disability linked to the disease. After 2-3 years of treatment the percentage of patients confined to a wheelchair was, in absolute values, 16.7% in the interferon beta-1b group and 24.6% in the placebo group. (4) In this trial the adverse effects linked to interferon beta-1b were already known, i.e. mainly a 'flu-like syndrome at the outset of treatment, and reactions at the injection site. (5) More than a quarter of patients on interferon beta-1b had neutralising antibodies against interferon beta-1b. More follow-up is needed to determine the possible impact of these antibodies on treatment efficacy and on the possible risk of autoimmune diseases. (6) Treatment with interferon beta-1b is still costly. |
| | |
Authors:
|
- |
Related Documents
:
|
21834769 - Novel design and synthesis of modified structure of carvedilol. 12119559 - Efficacy of long-term interferon therapy in chronic hepatitis b patients with hbv genot... 2792319 - Bone marrow morphology during alpha-interferon treatment in hairy cell leukemia. 20589379 - Early response assessment in patients with multiple myeloma during anti-angiogenic ther... 11694829 - The dynamic of adherence to highly active antiretroviral therapy: results from the fren... 18438569 - Difficulties reported by hiv-infected patients using antiretroviral therapy in brazil. 9663669 - A modified protocol for early treatment of osteomyelitis and osteoradionecrosis of the ... 3790909 - Results of surgical treatment for iliofemoral venous thrombosis. 20177689 - Neoadjuvant chemoradiotherapy, sepsis and neutrophil levels following radical excision ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Prescrire international Volume: 9 ISSN: 1167-7422 ISO Abbreviation: Prescrire Int Publication Date: 2000 Aug |
Date Detail:
|
Created Date: 2000-10-26 Completed Date: 2000-10-26 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9439295 Medline TA: Prescrire Int Country: FRANCE |
Other Details:
|
Languages: eng Pagination: 110-1 Citation Subset: T |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
administration & dosage,
adverse effects,
therapeutic use* Adolescent Adult Antigen-Antibody Reactions Clinical Trials as Topic Drug Approval France Humans Interferon-beta* / administration & dosage, adverse effects, therapeutic use Middle Aged Multiple Sclerosis, Chronic Progressive / drug therapy*, immunology Severity of Illness Index Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 77238-31-4/Interferon-beta |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pneumococcal vaccination for elderly subjects: license extension. Still no proof of clinical efficac...
Next Document: Sertraline and obsessive compulsive disorder: new indication. Limited assessment.